Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial
Eli Lilly and Company
Kevin Kalinsky; Giampaolo Bianchini; Erika Hamilton; Stephanie L Graff; Kyong Hwa Park; Rinath Jeselsohn; Umut Demirci; Miguel Martin; Rachel M Layman; Sara A Hurvitz; Sarah Sammons; Peter A Kaufman; Montserrat Muñoz; Jiun-I Lai; Holly Knoderer; Cynthia Sandoval; Aarti R Chawla; Bastien Nguyen; Yanhong Zhou; Elizabeth Ravenberg; Lacey M Litchfield; Lillian Smyth; Seth A Wander